BUCHAN JANE 4

What Happened
Jane Buchan, a director of Immix Biopharma (IMMX), received equity awards on 2026-05-22: 6,250 restricted stock units (RSUs) and a 12,500-share derivative award (stock option). Both awards were reported at an acquisition price of $0.00 (i.e., grants), so no cash changed hands at grant.

Key Details

• Transaction date: 2026-05-22; Form 4 filed 2026-05-29 (filed 7 days after the transaction; appears later than the usual two-business-day Form 4 deadline).
• Awards: 6,250 RSUs (grant) and 12,500 shares reported as a derivative award (stock option); both shown at $0.00 acquisition price.
• Vesting (per footnotes):
  • RSUs (6,250): vest in full on the earlier of one year after grant or the issuer’s 2027 annual meeting, subject to continued service.
  • Stock option (12,500): vests in substantially equal monthly installments over the 12 months following grant (or any remaining unvested portion vests on the 2027 annual meeting if it occurs earlier), subject to continued board service.
• Shares owned after the transaction: not specified in the supplied filing data.
• Type of transaction code: A = Award/Grant. No sale or purchase occurred.

Context

• These are compensatory equity grants to a director under the company’s equity plan (2021 Equity Incentive Plan), not open-market purchases or sales. Grants at $0 are standard for compensation and do not involve immediate cash outlay by the insider.
• Vesting conditions mean the economic benefit is deferred and contingent on continued service (and possibly the 2027 annual meeting). The filing does not indicate any immediate sale or cashless exercise.